Disc Medicine, Inc. (IRON)
NASDAQ: IRON · IEX Real-Time Price · USD
28.69
-1.33 (-4.43%)
At close: Apr 19, 2024, 4:00 PM
28.70
+0.01 (0.03%)
After-hours: Apr 19, 2024, 4:48 PM EDT
Disc Medicine Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Disc Medicine stock have an average target of 57.33, with a low estimate of 36 and a high estimate of 85. The average target predicts an increase of 99.83% from the current stock price of 28.69.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Disc Medicine stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 5 | 4 | 4 | 3 | 3 | 4 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Strong Buy Maintains $71 → $73 | Strong Buy | Maintains | $71 → $73 | +154.44% | Apr 8, 2024 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $75 → $40 | Hold | Maintains | $75 → $40 | +39.42% | Apr 2, 2024 |
| BMO Capital | BMO Capital | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Apr 2, 2024 |
| Stifel | Stifel | Strong Buy Maintains $104 → $71 | Strong Buy | Maintains | $104 → $71 | +147.47% | Apr 2, 2024 |
| Raymond James | Raymond James | Strong Buy → Buy Downgrades $40 | Strong Buy → Buy | Downgrades | $40 | +39.42% | Apr 1, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-4.76
from -3.42
EPS Next Year
-5.37
from -4.76
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | 13.1M | 163.6M | 223.8M |
| Avg | n/a | n/a | 2.7M | 61.7M | 147.3M |
| Low | n/a | n/a | n/a | 26.3M | 96.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | 5,913.6% | 262.6% |
| Avg | - | - | - | 2,168.9% | 138.7% |
| Low | - | - | - | 865.6% | 56.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.40 | -4.55 | -4.53 | 6.51 | 0.06 |
| Avg | -4.76 | -5.37 | -6.10 | -3.96 | -3.45 |
| Low | -7.39 | -6.90 | -7.97 | -9.33 | -7.97 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.